Phase II trial results of Validive® presented at the ASCO Conference

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that Validive® (clonidine Lauriad®) phase II clinical trial results have been accepted for a poster presentation at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO).

The ASCO annual meeting is a major event in the field of oncology that brings together 30,000 health professionals and updates on the major latest steps and results achieved in oncology worldwide. The event will be taking place in Chicago (USA), from May 29 to June 2, 2015.

Late October 2014, Onxeo reported positive preliminary top-line results of the large international Phase II clinical trial with Validive® in the prevention of oral mucositis in patients undergoing head and neck cancer treatment. They showed a reduction in the incidence of severe oral mucositis with a very good safety. Based on these data, the trial’s Board of experts has confirmed the interest of pursuing the development of Validive® with the initiation of a Phase III trial to evaluate the product’s efficacy. The company plans to initiate this trial in 2015.

“We are very pleased to have this presentation at the ASCO meeting, an opportunity to share the phase II clinical trial results of Validive® with the scientific community. The selection of our abstract emphasizes the expertise of our clinical development team and the quality of the data. It also confirms the interest of a key product of our orphan oncology portfolio that meets an unmet medical need in an invalidating pathology, comments Judith Greciet, CEO of Onxeo.

150402EN_Validive ASCO